Health Journalism · Supplementary · from Health Journalism

Case 2: Clinical Trial Reporting and Media Interpretation

Patient Presentation

Demographics: Not a clinical patient case. This is a media analysis case involving reporting on a newly published clinical trial.

Chief Complaint: "A pharmaceutical company issues a press release announcing that its new weight-loss drug resulted in 'revolutionary' 22% total body weight loss in a Phase 3 clinical trial. The press release is published in major news outlets with headlines such as 'New Drug Could End the Obesity Epidemic' and 'Most Effective Weight Loss Drug Ever Developed.' A health journalist must evaluate the trial, the press release, and produce accurate reporting."

History of Present Illness: A health journalist receives an embargoed copy of a Phase 3 randomized controlled trial published in a top-tier medical journal. The trial investigated a novel dual GIP/GLP-1/glucagon receptor tri-agonist ("triagonib") for obesity treatment. The press release from the pharmaceutical company emphasizes the headline figure of 22.1% mean body weight loss at 72 weeks.

The journalist must perform a critical appraisal of the trial, identify what the press release omits, contextualize the findings, and report accurately for a general audience without either overhyping or dismissing the results.

Past Medical History:

• Previous instances of clinical trial overhyping in media coverage leading to public disappointment and erosion of trust in science
• Fen-phen, rimonabant, and other weight-loss drugs withdrawn after initial enthusiasm
• Current GLP-1 RA medications (semaglutide, tirzepatide) as established context

Medications:

• N/A

Social History:

• Pharmaceutical company's stock price increased 18% after the press release
• Company has a direct-to-consumer marketing campaign planned for approval
• Patient advocacy groups expressing hope and concern simultaneously
• Insurance coverage debates anticipated

Family History:

• N/A

Physical Examination

• N/A (Media analysis case)

Workup and Results

Laboratory Studies:

Imaging/Additional Studies:

• Comparison with existing agents: semaglutide 2.4 mg achieves ~15% weight loss; tirzepatide 15 mg achieves ~21% weight loss; triagonib's 22.1% is incrementally higher but without head-to-head comparison, superiority cannot be determined
• NNT and NNH calculations: NNT for > 20% weight loss = 3.2; NNH for serious adverse event = 19
• GRADE assessment of evidence: Moderate certainty (downgraded for high dropout rate, short follow-up, no active comparator, industry funding)

Clinical Image

Infographic showing the key elements journalists should evaluate when reporting on clinical trial results: PICO framework (Population, Intervention, Comparison, Outcome), absolute vs relative risk, dropout rates and ITT vs per-protocol analysis, conflict of interest assessment, NNT/NNH, generalizability, and the difference between statistical significance and clinical significance. Source: Educational illustration.

Diagnosis

Selectively Presented Clinical Trial Results Requiring Contextualized Reporting

Key Diagnostic Criteria:

• Press release highlights best-case results (high-dose, per-protocol analysis) while omitting dropout rates, adverse effects, weight regain data, and lack of active comparator
• Genuine scientific advance (incremental improvement over existing agents) overstated as "revolutionary"
• Critical safety signals (pancreatitis, gallbladder events, thyroid concerns) minimized
• Long-term efficacy and safety data absent
• Significant financial conflicts of interest among authors
• Underrepresentation of racial and ethnic minorities limits generalizability

Treatment Plan

1. Accurate headline and framing:

• Avoid: "New Drug Could End the Obesity Epidemic" or "Most Effective Weight Loss Drug Ever"
• Better: "New Weight-Loss Drug Shows Promising Results in Clinical Trial, but Questions Remain About Long-Term Safety and Access"
• Include the ITT result (18.2%), not just the per-protocol result (22.1%)

1. Essential elements to include in reporting:

• The dropout rate (34% in the high-dose group) and why it matters
• The adverse effect profile with specific percentages, not just "generally well-tolerated"
• The weight regain data: 67% of weight regained within 12 months of stopping — this reframes the drug as requiring lifelong use, not a cure
• No active comparator: cannot claim superiority over existing GLP-1 RA medications
• Cost and access implications: at $1,400/month, who will have access?
• Diversity of the trial population: underrepresentation of the most affected communities

1. Contextualization:

• Place in context of existing medications (semaglutide, tirzepatide) — incremental, not revolutionary
• Discuss history of weight-loss drugs withdrawn for safety concerns
• Note that this is one trial, 72 weeks, and post-market surveillance will be critical
• Discuss the broader conversation: obesity as a chronic disease requiring sustained treatment, societal determinants, and the limitations of pharmacotherapy alone

1. Source selection for quotes:

• Include an independent obesity medicine specialist (not affiliated with the trial or company)
• Include a patient perspective (someone living with obesity, representing diverse experiences)
• Include a health economist or policy expert on access and cost
• Include the trial investigators (with disclosure of their conflicts)
• Do not rely solely on the company's press release or PR team

1. Follow-up stories:

• Investigate insurance coverage decisions and health equity implications
• Report on the planned cardiovascular outcome trial design and timeline
• Follow real-world effectiveness data vs clinical trial results
• Examine the pharmaceutical industry's press release practices and relationship with embargoed journalism

Key Learning Points

• Pharmaceutical press releases systematically overstate benefits and understate risks; journalists must read the full published paper, not rely on the press release, and should be trained in critical appraisal of clinical trial methodology
• The distinction between per-protocol analysis (only patients who completed the study) and intention-to-treat analysis (all randomized patients including dropouts) is critical; high dropout rates with per-protocol reporting inflate apparent efficacy
• Placebo-controlled trials without active comparators cannot establish superiority over existing treatments; "better than placebo" does not mean "better than current standard of care," and journalists should always ask "compared to what?"
• Weight regain after drug discontinuation is essential context that transforms the narrative from "cure" to "chronic management requiring lifelong treatment" with significant cost and access implications
• Reporting financial conflicts of interest is not optional; when 7 of 12 trial authors are company employees, this must be prominently disclosed and its potential impact on study design, analysis, and interpretation discussed

All cases for this lecture as Markdown